PubMed Health⌕ Search

Biomedical subjects

S Panek

Publications and source records attributed to S Panek.

5 recordsLinked to original sources
PubMed1985

The effect of 1-deamino 8 D-arginine vasopressin (DDAVP) in a nonhaemophilic patient with an acquired type II factor VIII inhibitor.

DDAVP (1-deamino 8 D-arginine vasopressin) was administered on two occasions to a patient with an acquired factor VIII inhibitor. Because the patient's autoantibody was low titre (1.8 Bethesda units) and had type II kinetic properties, it was expected that endogenous factor VIII/VWF released by DDAVP would be inactivated at a slow enough rate to permit satisfactory haemostasis during dental procedures. In both instances there was a 7-9-fold increase in factor VIII above the baseline level (13 units/dl), and factor VIII activity remained above 35 units/dl for 5 h after the infusion. The inhibitor could not be detected in his plasma during this period and the activated PTT was shortened into the normal range. Our experience with this patient suggests that DDAVP has a role in the management of some patients with low titre autoantibodies that inactivate factor VIII.

Arginine Vasopressin↗
PubMed1984

Labile coagulation factors in thawed fresh frozen plasma prepared by two methods.

Two preparations of fresh frozen plasma were studied. The plasma from CPDA-1 whole blood units was either frozen within 6 h (FFP-I) or 18-20 h (FFP-II) of phlebotomy. Average activity for factor VIII for FFP-I (n = 6) and FFP-II (n = 19) was 102% and 55%, respectively (p less than 0.01). Average activity for factor V and VII in both products was approximately 100%. Factor XI activity (n = 13) in FFP-II averaged 84%. We conclude that FFP-I and FFP-II are equivalent in terms of coagulation factor activity except for factor VIII.

Blood Coagulation Factors↗
PubMedDate not supplied

Reemergence of the International Normalized Ratio for the standardization of prothrombin time.

A survey of physicians demonstrated that half had knowledge of the International Normalized Ratio (INR) but none used the value for monitoring their patients because it was not available from the Coagulation Laboratory. The Laboratory then provided the INR value at a physician's request. A six month review of prothrombin time (PT) results showed that only the physicians from the Cardiology Clinic and the Hematology Clinic employed the INR for monitoring their patients. General Medical and Surgical, Vascular, and Orthopedic Clinics continued to use the PT in seconds. This dichotomy allowed the unique opportunity to compare variability of PT in patients followed by INR and those followed by PT in seconds. Inpatients on daily monitoring were used as the standard for close control. During a six month period, laboratory reports from all patients having regular PTs and/or INRs recorded were analyzed for mean level of PT maintained, variability between individual PTs in any given patient, and instances when the PT changed > or = 5 seconds (sec) or increased to > or = 30 sec. Physicians intended to keep the PTs between 16 and 19 sec (INR 2.0 to 3.0). Results showed statistically significantly lower values of PT, less variation in values of PT and a smaller fraction of patients with changes in PT of > or = 5 sec in the group followed by INR. This group was comparable to the inpatient group but significantly different from the outpatient group followed by PT in sec.(ABSTRACT TRUNCATED AT 250 WORDS)

Drug Monitoring↗